Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBT (2016 - 2025)

OptimizeRx (OPRX) has disclosed EBT for 16 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly EBT rose 238.36% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 135.85% year-over-year, with the annual reading at $7.0 million for FY2025, 135.85% up from the prior year.
  • EBT hit $7.5 million in Q4 2025 for OptimizeRx, up from $1.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $7.5 million in Q4 2025 to a low of -$11.7 million in Q4 2023.
  • Historically, EBT has averaged -$2.4 million across 5 years, with a median of -$3.1 million in 2023.
  • Biggest five-year swings in EBT: plummeted 8790.01% in 2022 and later surged 238.36% in 2025.
  • Year by year, EBT stood at $623462.0 in 2021, then plummeted by 152.26% to -$325836.0 in 2022, then crashed by 3503.04% to -$11.7 million in 2023, then soared by 118.81% to $2.2 million in 2024, then soared by 238.36% to $7.5 million in 2025.
  • Business Quant data shows EBT for OPRX at $7.5 million in Q4 2025, $1.0 million in Q3 2025, and $1.7 million in Q2 2025.